Rasburicase Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of rasburicase during breastfeeding. Because it is a large protein molecule with a molecular weight of about 34,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably partly destroyed in the infant's gastrointestinal tract.[1,2] However, the manufacturer recommends that breastfeeding be discontinued during rasburicase therapy and for 2 weeks after the final dose. An alternate drug can be considered.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003 [CrossRef]
2.
Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med 2021;16:591-3. [PubMed: 33956488]
Substance Identification
Substance Name
Rasburicase
CAS Registry Number
134774-45-1
Drug Class
Breast Feeding
Lactation
Milk, Human
Enzymes
Gout Suppressants
Urate Oxidase
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
